Lyka Labs (LYKALABS.NS) Stock Price

Lyka Labs Price

CLOSED
75.84
​
Market closed

Revenue has compounded at 5.0% per year over the past 21 years to 1.28 B INR. Earnings per share have grown at 4.0% per year over the last 17 years. Lyka Labs's net margin stands at -7.8%, down from 21.2% several years earlier.

Lyka Labs stock price

Access this data via the Eulerpool API

Lyka Labs business model & stock analysis

Lyka Labs Ltd. is a holding company, which engages in the manufacture of pharmaceutical formulations and active pharmaceutical ingredients. The company is headquartered in Mumbai, Maharashtra. The firm is focused on lyophilization - formulations/bulk sterile active pharmaceutical ingredients (APIs), and new product development including novel drug delivery systems in both topical preparation and lyophilized products. The firm manufactures pharmaceutical products, such as dry powder, liquid injections, lyophilized injections, ointment/creams and lotions, and external preparations for several international markets and the domestic market. The company offers formulations, such as emollient, anti-aging, cleansing lotion, hair care products, anti-dandruff shampoo, sunscreen, anti-acne, antioxidant tablets, antioxidants combination, proton pump inhibitor, anti-fungal, anti-malarial, anti-bacterial, corticosteroid hormones and cephalosporins. The firm's subsidiaries include Lyka BDR International Limited and Lyka Exports Limited.

Frequently asked questions about Lyka Labs

Converted at the current exchange rate, the Lyka Labs share trades at 0.71 EUR (75.84 INR).

The revenue of Lyka Labs is 1.28 B INR. This figure is based on current financial data and reflects the company's business performance.

The profit of Lyka Labs is -100.32 M INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Lyka Labs is currently -27.33. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Lyka Labs stock.

The price-to-sales ratio (P/S) of Lyka Labs is currently 2.13. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Lyka Labs stock.

The Eulerpool Quality Score for Lyka Labs is 2/10.

The ISIN of Lyka Labs is INE933A01014. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Lyka Labs is LYKALABS.NS. The ticker symbol is used to trade Lyka Labs shares on the stock exchange.

Fair ValueTerminal
65.98 INR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website lykalabs.com
Country
Currency
INR
Initial public offering
Feb 9, 1995
ISIN
INE933A01014
Cusip
Y53614114
Market capitalization
2.71 B INRMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
2.93
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-7.10 %
Last updated Oct 14, 2026, 11:57 PM

Lyka Labs Peer Group

Lyka Labs FIGI

LYKA:IN · BBG000CVSPG4LYKA:IB · BBG000CVSQB7LYKA:IS · BBG000CVSRN2LYKA:IG · BBG003NVX360

All fundamentals and in-depth analysis of Lyka Labs

Our stock analysis for Lyka Labs stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lyka Labs. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.